1. Home
  2. BLMN vs CTMX Comparison

BLMN vs CTMX Comparison

Compare BLMN & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BLMN
  • CTMX
  • Stock Information
  • Founded
  • BLMN 1988
  • CTMX 2008
  • Country
  • BLMN United States
  • CTMX United States
  • Employees
  • BLMN N/A
  • CTMX N/A
  • Industry
  • BLMN Restaurants
  • CTMX Biotechnology: Pharmaceutical Preparations
  • Sector
  • BLMN Consumer Discretionary
  • CTMX Health Care
  • Exchange
  • BLMN Nasdaq
  • CTMX Nasdaq
  • Market Cap
  • BLMN 625.3M
  • CTMX 596.2M
  • IPO Year
  • BLMN 2012
  • CTMX 2015
  • Fundamental
  • Price
  • BLMN $7.49
  • CTMX $3.39
  • Analyst Decision
  • BLMN Hold
  • CTMX Strong Buy
  • Analyst Count
  • BLMN 9
  • CTMX 5
  • Target Price
  • BLMN $9.25
  • CTMX $5.80
  • AVG Volume (30 Days)
  • BLMN 1.8M
  • CTMX 3.0M
  • Earning Date
  • BLMN 11-06-2025
  • CTMX 11-07-2025
  • Dividend Yield
  • BLMN 7.99%
  • CTMX N/A
  • EPS Growth
  • BLMN N/A
  • CTMX 263.20
  • EPS
  • BLMN N/A
  • CTMX 0.49
  • Revenue
  • BLMN $3,933,993,000.00
  • CTMX $141,100,000.00
  • Revenue This Year
  • BLMN $1.43
  • CTMX N/A
  • Revenue Next Year
  • BLMN $1.40
  • CTMX N/A
  • P/E Ratio
  • BLMN N/A
  • CTMX $6.79
  • Revenue Growth
  • BLMN 2.47
  • CTMX 18.01
  • 52 Week Low
  • BLMN $6.09
  • CTMX $0.40
  • 52 Week High
  • BLMN $17.57
  • CTMX $3.91
  • Technical
  • Relative Strength Index (RSI)
  • BLMN 49.44
  • CTMX 57.06
  • Support Level
  • BLMN $7.40
  • CTMX $3.21
  • Resistance Level
  • BLMN $8.17
  • CTMX $3.50
  • Average True Range (ATR)
  • BLMN 0.33
  • CTMX 0.25
  • MACD
  • BLMN 0.00
  • CTMX -0.06
  • Stochastic Oscillator
  • BLMN 46.21
  • CTMX 35.42

About BLMN Bloomin' Brands Inc.

Bloomin Brands Inc operates as a casual dining restaurant company. The company's brand includes Outback Steakhouse, Carrabba's Italian Grill, Bonefish Grill, and Fleming's Prime Steakhouse and Wine Bar. The company owns and operates its restaurants, and the remainder is franchised. It derives revenue mainly from the United States, but the company has a presence in Brazil and South Korea with company-owned Outbacks and Carrabbas. In addition, it also has exposure to several countries, predominantly in Asia, principally through franchising. The Company aggregates its operating segments into two reportable segments, U.S. and international. The U.S. segment includes all restaurants operating in the U.S. while restaurants operating outside the U.S. are included in the international segment.

About CTMX CytomX Therapeutics Inc.

CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

Share on Social Networks: